PETROCHINA (00857) plans to elect Wu Jianing as an independent non-executive director.
China Petroleum & Chemical Corporation (00857) announced that the term of office of the directors of the ninth board of directors will expire on the day of the Company's 2025 annual general meeting.
PETROCHINA (00857) announced that the term of office of the directors of the ninth board of directors will expire on the day of the Company's 2025 annual general meeting. The board of directors (i) proposed the re-election and appointment of Mr. Dai Houliang as a director, Mr. Zhou Xinhuai as a non-executive director, Mr. Duan Liangwei as a non-executive director, Mr. Zhou Song as a non-executive director, Mr. Ren Lixin as an executive director, Mr. Xie Jun as a non-executive director, Mr. Zhang Daowei as an executive director, Mr. Song Dayong as an executive director, Mr. He Jinglin as an independent non-executive director, Mr. Yan Yan as an independent non-executive director, Ms. Liu Xiaolei as an independent non-executive director, and Mr. Zhang Yuxin as an independent non-executive director; (ii) election and appointment of Wu Jianing as an independent non-executive director. The proposals for the re-election and appointment of directors and the election and appointment of independent non-executive directors will be submitted for consideration and approval by the Company's shareholders at the annual general meeting through ordinary resolutions.
Related Articles

New Stock News | Aqara International Ltd. Submits Application to Hong Kong Stock Exchange

TOP SPRING (03688) issues profit warning, expecting a net loss of HKD 3 billion for the year 2025.

Hansoh Pharma (03692) released its annual performance with a net profit attributable to shareholders of 5.55 billion yuan, representing a year-on-year increase of 27.07%.
New Stock News | Aqara International Ltd. Submits Application to Hong Kong Stock Exchange

TOP SPRING (03688) issues profit warning, expecting a net loss of HKD 3 billion for the year 2025.

Hansoh Pharma (03692) released its annual performance with a net profit attributable to shareholders of 5.55 billion yuan, representing a year-on-year increase of 27.07%.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


